Related Experiment Videos
Anticoagulant therapy, anti-platelet agents and gastrointestinal endoscopy
A M Miller1, D McGill, M L Bassett
1Gastroenterology Unit, The Canberra Hospital, Garran, ACT, Australia.
Insights
Managing anticoagulant and anti-platelet therapy before gastrointestinal endoscopy is crucial. Guidelines help balance bleeding risks during endoscopy with thromboembolic risks from stopping these vital medications.
Area of Science:
- Gastroenterology
- Cardiology
- Pharmacology
Background:
- Anticoagulant and anti-platelet agents are increasingly used for preventing thromboembolic events.
- Gastrointestinal endoscopy necessitates careful management of these medications due to bleeding risks.
- Temporary cessation of anticoagulation increases thromboembolic risks for patients.
Purpose of the Study:
- To review existing literature on managing anticoagulant and anti-platelet therapy during gastrointestinal endoscopy.
- To propose evidence-based guidelines for clinicians.
Main Methods:
- Literature review of studies on anticoagulant/anti-platelet management and gastrointestinal endoscopy.
- Synthesis of findings to develop clinical recommendations.
Main Results:
- Continuation of anticoagulant therapy increases post-endoscopy hemorrhage risk.
- Discontinuation of anticoagulant therapy elevates thromboembolic event risk.
- Balancing these risks requires individualized patient management strategies.
Conclusions:
- Guidelines are needed for managing patients on anticoagulant and anti-platelet agents undergoing gastrointestinal endoscopy.
- Proposed guidelines aim to minimize both hemorrhagic and thromboembolic complications.
- This review provides a framework for clinical decision-making in this patient population.
Background:
The increasing use of anticoagulant therapy and anti-platelet agents in the primary and secondary prevention of cardiovascular, cerebrovascular and venous thromboembolic disease has increased the need for guidelines for managing these agents prior to gastrointestinal endoscopy, particularly if therapeutic manoeuvres are required. The continuation of anticoagulant therapy increases the risk of haemorrhagic complications of gastrointestinal endoscopy. Temporary suspension of anticoagulant therapy exposes the patient to the risk of thromboembolism associated with the underlying condition requiring anticoagulant treatment.
Conclusions:
This article reviews the literature and proposes guidelines for the management of patients taking anticoagulant and anti-platelet agents who require gastrointestinal endoscopy.